The antidiabetic drug metformin exerts pleiotropic effects on multiple organs, including the
cardiovascular system. Evidence has shown that metformin improves healthspan and …

Chemotherapy resistance is one of the major challenges in cancer treatment, including
leukemia. A massive array of research is evaluating combinations of drugs directed against …

Abstract Group 3 medulloblastoma (G3 MB) carries the worst prognosis of all MB subgroups.
MYC oncoprotein is elevated in G3 MB tumors; however, the mechanisms that support MYC …

Nandrolone is a testosterone analogue with anabolic properties commonly abused
worldwide, recently utilized also as therapeutic agent in chronic diseases, cancer included …

The antiaging properties of metformin used for the treatment of type-2 diabetes mellitus have
been studied extensively, but there is more to discover regarding underlying mechanisms …

Beyond glycemic control, SGLT2 inhibitors (SGLT2i) have protective effects on cardiorenal
function. Renoprotection has been suggested to involve inhibition of NHE3 leading to …

Anlotinib is a novel multi-targeted tyrosine kinase inhibitor with activity against soft tissue
sarcoma, small cell lung cancer, and non-small cell lung cancer (NSCLC). Potentiating the …

Modulation of autophagy as an anticancer strategy has been widely studied and evaluated
in several cell models. However, little attention has been paid to the metabolic changes that …

Cancer stem cells (CSCs) have been identified in various tumor types. CSCs are believed to
contribute to tumor metastasis and resistance to conventional therapy. So targeting these …

Several studies reported that metformin, the most widely used drug for type 2 diabetes, might
affect cancer aggressiveness. The biguanide seems to directly impair cancer energy asset …